Position in NVS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$303,409
+$250,982 QoQ
Shares Held
1,936
+257.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#1,127
of 1,603 holders
Holding Since
Dec 2023
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $4,359,430 across 8 Drug Manufacturers - General names. NVS ranks #5 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
13,595 | $1,717,592 | |
| 2 | PFE |
Pfizer Inc
|
40,976 | $986,702 | |
| 3 | BIIB |
Biogen Inc.
|
1,716 | $370,758 | |
| 4 | GSK |
GSK plc
|
6,632 | $347,649 | |
| 5 | NVS |
Novartis AG
This page
|
1,936 | $303,409 | |
| 6 | AMGN |
Amgen Inc
|
654 | $236,826 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
3,499 | $201,612 | |
| 8 | AMRN |
Amarin Corp Plc\Uk
|
12,226 | $194,882 |
All Filings in NVS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $303,409 | 1,936 | Shares | Sole | 2026-08-13 | |
| 2024-03-31 | $52,427 | 542 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $100,970 | 1,000 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||